Vaccine journal publishes results of Emergent Phase Ia study of anthrax vaccine

In the study, which enrolled 69 subjects, the addition of the CPG 7909 adjuvant to BioThrax (Anthrax Vaccine Adsorbed), the only US Food and Drug Administration (FDA) licensed anthrax vaccine, accelerated and enhanced the immune response to the vaccine in healthy volunteers. Trial subjects received...

Full description

Saved in:
Bibliographic Details
Published inM2 Pharma
Format Newsletter
LanguageEnglish
Published London Normans Media Ltd 26.08.2011
Subjects
Adjuvants
Clinical trials
Medical research
Vaccines
United States > US
Online AccessGet full text

Cover

More Information
Summary:In the study, which enrolled 69 subjects, the addition of the CPG 7909 adjuvant to BioThrax (Anthrax Vaccine Adsorbed), the only US Food and Drug Administration (FDA) licensed anthrax vaccine, accelerated and enhanced the immune response to the vaccine in healthy volunteers. Trial subjects received three doses of either: BioThrax alone, 1 mg of CPG 7909 alone or BioThrax plus 1 mg of CPG 7909, all given intramuscularly on study days zero, 14, and 28. Data from the trial showed that BioThrax plus CPG 7909 generated peak antibody responses that were six-fold higher than those generated by BioThrax alone.